Skip to main content

Publisher Correction: Lessons learned and implications of early therapies for coronavirus disease in a territorial service centre in the Calabria region: a retrospective study

The Original Article was published on 20 October 2022

Publisher Correction: BMC Infectious Diseases (2022) 22:793 https://doi.org/10.1186/s12879-022-07774-9

In the original publication of this article [1] the footnotes of Figure 1 were accidentally omitted during the publication process. In this correction article: Fig. 1 with the footnotes is published. The original article has been updated to rectify this error. The publisher apologizes to the authors and readers for the inconvenience caused.

Fig. 1
figure 1

Flow chart of drugs prescription choices according to risk of progression of COVID-19. *Presence of at least one of the following factors: age > 65 years, BMI ≥ 30, patients chronically subjected to peritoneal dialysis or haemodialysis, uncontrolled diabetes mellitus or with chronic complications, primitive or secondary immunodeficiency (particularly concerning patients being treated with immunosuppressive drugs or less than 6 months from suspension of treatment), cardiocerebrovascular disease (including arterial hypertension with organ damage), COPD and/or other chronic respiratory diseases (lung fibrosis or patient needing O2-therapy for reasons different from SARS-CoV-2 infection), active oncological or oncohematological disease, chronic hepatopathy, hemoglobinopathies, neurodegenerative disorders. 1Patients affected by haematological malignancies/autoimmune diseases or treated with immunosuppressive drugs or transplant receivers; 2First choice in patients with eGFR > 30 ml/min and no major drug interactions; 3Useful in patients with eGFR > 30 ml/min if major drug interactions contraindicate nirmatrelvir/ritonavir or in patients with dysphagia; 4For use in patients with severe renal insufficiency and/or partially immunised (i.e., previous SARS-CoV-2 infection, vaccination course incomplete or completed more than 6 months before); 5mAbs therapy was chosen considering local epidemiology of variants of concern

Reference

  1. Scaglione V, Rotundo S, Marascio N, De Marco C, Lionello R, Veneziano C, Berardelli L, Quirino A, Olivadese V, Serapide F, Tassone B, Morrone HL, Davoli C, La Gamba V, Bruni A, Cesana BM, Matera G, Russo A, Costanzo FS, Viglietto G, Trecarichi EM, Torti C, IDTM U. M. G. COVID-19 Group. Lessons learned and implications of early therapies for coronavirus disease in a territorial service centre in the Calabria region: a retrospective study. BMC Infect Dis. 2022;22:793. https://doi.org/10.1186/s12879-022-07774-9.

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Consortia

Corresponding author

Correspondence to Carlo Torti.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Scaglione, V., Rotundo, S., Marascio, N. et al. Publisher Correction: Lessons learned and implications of early therapies for coronavirus disease in a territorial service centre in the Calabria region: a retrospective study. BMC Infect Dis 22, 883 (2022). https://doi.org/10.1186/s12879-022-07871-9

Download citation

  • Published:

  • DOI: https://doi.org/10.1186/s12879-022-07871-9